Cinda Bio published the results of the clinical study of the first-line treatment of liver cancer phase III of the Cindili monoanti-anti-combined beval beval bead mono-anti-first-line

On November 21, 2020, Thysta Biopharmaceuticals (HKEx: 01801) published the results of THEIENT-32 clinical studies in the form of a preferred oral report at the 2020 European Society of Oncology Asia Annual Meeting (ESMO ASIA). United? Significantly prolongs total survival (OS) and progress-free survival (PFS) in patients with liver cancer.
cancer is a common digestive malignancy in the world, China's liver cancer patients accounted for about half of the global number of liver cancer, liver cancer seriously threatens the lives and health of our people.
pathological types of liver cancer are mainly hepatocellular carcinoma (HCC), accounting for 85% to 90%, and a few are liver bile tube cancer (ICC) and HCC-ICC hybrids.
in China, HCC is mainly caused by hepatitis B virus and/or hepatitis C virus infection.
ORIENT-32 is a comparison of Dabershu? United? The randomized, controlled, open multi-center Phase III clinical study (ClinicalTrials.gov, NCT 03794440) with the efficacy and safety of Sorapinib in first-line treatment of advanced liver cancer (HBV) is also the world's first PD-1 inhibitor combined to treat the first-line treatment of late-stage hepatitis B virus (HBV)-related liver cancer as the primary population for randomized, open, multi-center Phase III studies.
the study, a total of 571 subjects in the group were randomly assigned to the 2:1 group. United? or solacini for treatment.
study endpoints are OS and progress-free lifetime PFS assessed by the Independent Imaging Review Board (IRRC) based on the RECIST v1.1 standard.
an in-period analysis conducted by the Independent Data Monitoring Board (IDMC), Dabershu? (Xindili monoanti-injection) United? (Beval pearl monoantigen injection) Pisolafine monotherapy significantly extends total lifetime (OS) and progress-free lifetime (PFS) to meet preset prosaicity standards.
compared to the Sorafini group, Dabershu? United? Group risk of death decreased by 43.1% (HR 0.569, 95% CI: 0.431-0.751, P.lt;0.0001); United? The middle OS in the group has not yet been reached, and the mid-OS in the Sorafeini group is 10.4 months.
risk of disease progressity assessed by the Independent Imaging Commission (IRRC) based on RECIST 1.1 decreased by 43.5 per cent. United? The middle PFS in the group is 4.6 months and the middle PFS in the Sorafini group is 2.8 months.
subgroup analysis showed that all subgroup combined treatment groups benefited.
treatment options have acceptable safety and no new safety signals.
Daboshu? United? The therapy promises to offer new options for first-line treatment in patients with liver cancer who cannot be removed or metastatic.
Hui, Vice President of Medical Science and Strategic Oncology at Essinda Biopharmaceutical Group, said, "We are very pleased to see that the study confirms that Dabershu? United? OS and PFS were significantly extended in people treated with first-line liver cancer in China.
will apply to the National Drug Administration as soon as possible? United? New adaptations are on the market, allowing the treatment to benefit more patients with liver cancer.
"Biological Exploration Source: Bio-Discovery Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here